Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib versus pemetrexed plus platinum as first-line therapy in ALK-positive advanced non-squamous NSCLC
NL-OMON38269Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of crizotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Sep 2012; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON38269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38269.